Revenue Up 5.2% Year-on-Year
Operating Profit 45.6 Billion Won, Net Profit 41.6 Billion Won

Huons continued its growth trajectory last year by posting the highest quarterly revenue in its history. The company also presented a mid- to long-term dividend policy for shareholder returns.

Hyuonseu company logo image. Hyuonseu

Hyuonseu company logo image. Hyuonseu

View original image

Huons announced on the 13th that on a consolidated basis, it recorded revenue of 620.8 billion won, operating profit of 45.6 billion won, and net profit of 41.6 billion won for 2025. Compared with the previous year, revenue increased by 5.2%, operating profit by 14.9%, and net profit by 43.2%.

Fourth-quarter revenue came to 165.2 billion won, marking a new quarterly record. During the same period, operating profit was 9.8 billion won, down 10.6%, while net profit was 9.2 billion won, up 135%.


The company decided on a year-end cash dividend of 200 won per share. Based on the 2025 fiscal year, the total dividend per share, including semiannual and quarterly dividends, was 920 won, up 46% from the previous year. The total dividend payout amounted to 10.7 billion won.


This year, the company plans to pay a cash dividend of 200 won per share each quarter, for an annual total of 800 won per share. Going forward, it intends to increase the annual dividend per share by 5% to 30% each year through 2028. The dividend resources will be secured through a capital reduction dividend using a reduction in capital surplus, thereby providing tax-exempt benefits.


The improvement in earnings was driven by an expansion in exports. Last year’s export sales reached 64.3 billion won, a 24.4% increase from the previous year. In particular, exports of injectable products to North America rose 52.3% to 18.4 billion won. New exports of sodium carboxymethylcellulose eye drops to the United States were added, and exports of health functional foods also expanded.


The cost ratio rose due to the expansion of the injectable line at the second plant and the impact of GMP approval, but the company protected profitability by reducing selling, general, and administrative expenses. The new injectable plant at the second site has now begun commercial production and is expected to contribute to earnings from the first quarter of this year.


The performance of subsidiaries also improved. Huonsen and Huons Bio Pharma turned profitable, and PanGen, which was consolidated in June last year, also showed earnings growth. Along with reorganizing its health functional food business, Huonsen strengthened its export responsiveness by acquiring Bio Loget, a manufacturer of health functional foods.



Huons has set a revenue target of 646.2 billion won for this year. The company plans to sustain its growth by fully operating the injectable line at the second plant and expanding global exports, while increasing research and development investment to strengthen the competitiveness of its pipeline.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing